Compare Sibanye Stillwater Ltd (SBSW) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs Tilray Brands Inc — how do they compare? Sibanye Stillwater Ltd trades at $10 (market cap $6.88B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Sibanye Stillwater Ltd is far larger — about 13× Tilray Brands Inc's market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sibanye Stillwater Ltd for 51 Days and Tilray Brands Inc for 31 Days on average.
| SBSW | TLRY | |
|---|---|---|
Market Cap | $6.88B | $530.54M |
Volume | 4,474,536 | 9,099,075 |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $17.20 |
52-Week Low | $8.00 | $3.54 |
Typical Hold Time | 51 Days | 31 Days |
Enterprise Value | $7.78B | $684.46M |
Dividend Yield | 8.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBSW trades at $9.91, up 2.38% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $5.17 billion in 2025 despite revenue of $129.68 billion, though 2026 projections show a return to profitability. Recent news highlights strong first-half 2026 results, including 54% revenue growth and a 111% EBITDA increase, driving positive sentiment.
The outlook is mixed: analyst consensus is a 'Buy' with a $14.25 price target, implying 44% upside, supported by operational improvements and commodity price strength. Risks include volatile earnings, high debt levels, and exposure to commodity cycles. Upside hinges on sustained execution of the growth roadmap and cost discipline.
TLRY trades at $3.59, down 3.36% on the day and near 52-week lows, with a bearish technical signal. The company reported revenue of $821.31M for 2025 but posted a net loss of -$2.19B, missing earnings expectations for four consecutive quarters. While analyst consensus shows 70% hold ratings, the stock faces significant profitability challenges with negative margins and cash flow concerns despite some revenue growth projections.
The outlook remains challenging with persistent losses and negative cash flow, though the stock trades at discounted valuation multiples. Key risks include ongoing profitability struggles and cannabis regulatory uncertainty. Potential catalysts include upcoming Q1 2027 earnings on October 8, 2026, and potential marijuana reform developments that could benefit the company's positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
